Literature DB >> 12473787

An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses.

Subrata Chattopadhyay1, Elizabeth Kriscenski-Perry, David A Wenger, David A Pearce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12473787     DOI： 10.1212/01.wnl.0000041913.97883.8b

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  11 in total

1.  Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Samantha L Hersrud; Attila D Kovács; David A Pearce
Journal:  Biochim Biophys Acta       Date:  2016-04-19

2.  Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Authors:  Erika F Augustine; Christopher A Beck; Heather R Adams; Sara Defendorf; Amy Vierhile; Derek Timm; Jill M Weimer; Jonathan W Mink; Frederick J Marshall
Journal:  JIMD Rep       Date:  2018-06-20

3.  High levels of Anti-GAD65 and Anti-Ro52 autoantibodies in a patient with major depressive disorder showing psychomotor disturbance.

Authors:  Kathryn H Ching; Peter D Burbelo; Paul J Carlson; Wayne C Drevets; Michael J Iadarola
Journal:  J Neuroimmunol       Date:  2010-03-12       Impact factor: 3.478

4.  Immunosuppression alters disease severity in juvenile Batten disease mice.

Authors:  Sabrina S Seehafer; Denia Ramirez-Montealegre; Andrew Ms Wong; Chun-Hung Chan; Julian Castaneda; Michael Horak; Sarah M Ahmadi; Ming J Lim; Jonathan D Cooper; David A Pearce
Journal:  J Neuroimmunol       Date:  2011-01       Impact factor: 3.478

Review 5.  Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease).

Authors:  Madhu M Ouseph; Mark E Kleinman; Qing Jun Wang
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

6.  High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome.

Authors:  Peter D Burbelo; Sandra Groot; Marinos C Dalakas; Michael J Iadarola
Journal:  Biochem Biophys Res Commun       Date:  2007-11-29       Impact factor: 3.575

Review 7.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 8.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

9.  Combined Anti-inflammatory and Neuroprotective Treatments Have the Potential to Impact Disease Phenotypes in Cln3 -/- Mice.

Authors:  Marta A Tarczyluk-Wells; Christoph Salzlechner; Allison R Najafi; Ming J Lim; David Smith; Frances M Platt; Brenda P Williams; Jonathan D Cooper
Journal:  Front Neurol       Date:  2019-09-11       Impact factor: 4.003

Review 10.  Cellular models of Batten disease.

Authors:  Christopher J Minnis; Christopher D Thornton; Lorna M FitzPatrick; Tristan R McKay
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-10-23       Impact factor: 5.187
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.